Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lutathera
Pharma
Novartis eyes $1B Lutathera acceleration with first-line win
Novartis hopes new data will open a $1 billion market opportunity for its radioligand therapy, Lutathera, as a first-line treatment.
Angus Liu
Jan 19, 2024 10:00am
Novartis commits $85M to build radiotherapy plant in China
Dec 1, 2023 11:06am
With trial win, Novartis eyes first-line use for Lutathera
Sep 25, 2023 10:33am
Novartis expands radiotherapy facilities as production halt ends
Jun 30, 2022 10:01am
Novartis radiotherapy patients to receive meds again in June
Jun 2, 2022 8:43am
Novartis halts US production of 2 cancer drugs, citing quality
May 5, 2022 12:44pm